Sutro Biopharma Overview
DCF fair value estimate for Sutro Biopharma: $-0.82.
Get informed when a big investor buys or sells
+ Follow$-0.82
Overvalued by 104.0% based on the discounted cash flow analysis.
Sutro Biopharma (STRO) currently reports a DCF fair value of $-0.82. Use the charts on this page to explore Sutro Biopharma's DCF fair value history and peer comparisons.
Sutro Biopharma's discounted cash flow (DCF) fair value estimate is $-0.82, about 104.0% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.
Start with the current DCF fair value of $-0.82, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sutro Biopharma, and consider following STRO for alerts when major investors trade the stock.
Sutro Biopharma is classified in the Healthcare sector. On DCF fair value, it currently shows $-0.82. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing STRO with unrelated industries.
